Trial Title:
Tris-CAR-T Cell Therapy for Recurrent Glioblastoma
NCT ID:
NCT05577091
Condition:
Recurrent Glioblastoma
Conditions: Official terms:
Glioblastoma
Recurrence
Conditions: Keywords:
Recurrent Glioblastoma
Immunotherapy
Adverse Events
Study type:
Interventional
Study phase:
Phase 1
Overall status:
Recruiting
Study design:
Allocation:
N/A
Intervention model:
Single Group Assignment
Intervention model description:
Recipients with the Ommaya reservoir implanted will be assigned to three courses. Arm A:
Two patients, 1×10^7 autologous Tris-CAR-T, at least 1 dose, maximum 6 doses. Arm B: Two
patients 1×10^8 autologous Tris-CAR-T, at least 1 dose, maximum 6 doses. Arm C: Six
patients 5×10^7 autologous Tris-CAR-T, maximum 8 doses.
Primary purpose:
Treatment
Masking:
None (Open Label)
Intervention:
Intervention type:
Genetic
Intervention name:
Inverse correlated dual-target, truncated IL7Ra modified CAR -expressing autologous T-lymphocytes.
Description:
Intratumoral or intraventricular administration via Ommaya reservoir.
Dose level 0: 1×10^7 autologous Tris-CAR-T cells, at least one dose, maximum 6 doses, 2
patients.
Dose level 1: 1×10^8/ 5×10^6 autologous Tris-CAR-T cells, at least one dose, maximum 6
doses, 2 patients. The dose of Dose level 1 will refer to the adverse effect of Dose
level 0. When dose-related side effects occurred in 2 patients in the Dose level 0, the
dose should be reduced to 5×10^6 cells.
In Dose levels 0 and 1, the second dose will be infused 28 days after the first dose, and
the subsequent doses will be administered weekly.
Dose level 2: 5×10^7 autologous Tris-CAR-T cells, weekly administered, maximum 8 weeks, 4
patients. If the results of Dose levels 0 and 1 suggested that dose-related toxic side
effects could have occurred in the 1×10^7cells dose, the researcher would re-determine
the dosage of the multidose clinical exploration study.
Arm group label:
Autologous Tris-CAR-T cell
Other name:
Autologous Tris-CAR-T cell.
Summary:
This is a Phase 1 study of recurrent glioblastoma locoregional adoptive therapy with
autologous peripheral blood T cells lentivirally transduced to express a dual-target,
truncated IL7Ra modified chimeric antigen receptor (CAR), delivered by Ommaya reservoir,
a pre-indwelled catheter in the tumor resection cavity or ventricle. Patients with
pathological confirmation of glioblastoma and radiological evidence of recurrence are
candidates for this clinical trial. If the patient meets all other eligibility criteria,
and meets none of the exclusion criteria, will have leukapheresis, and a subsequent
Ommaya reservoir implantation. T cells will be isolated from the PBMC sample and then be
bioengineered into a 4th generation CAR-T cell, Tris-CAR-T cells.
Recipients will be assigned to three courses in the order of enrollment. The first 2
patients will be assigned to the low-dose group. The second 2 patients will be assigned
to the high dose group. The first 4 patients will have at least one dose of autologous
Tris-CAR-T cells delivery via the Ommaya reservoir, at a maximum of 6 doses. The interval
between the first and the second dose is 28 days, and the rest doses will be administered
weekly. The last 6 patients will be assigned to the consecutive multidose group, and will
receive a weekly dose of autologous Tris-CAR-T cells for a maximum of 8 weeks. All
patients will undergo studies including MRI to evaluate the effect of the CAR-T cells,
physical examination, and cerebrospinal fluid cytokine assays to evaluate side effects.
All patients will undergo a long-term follow-up.
The hypothesis is that an adequate amount of Tris-CAR-T cells can be manufactured to
complete all the three courses. The other hypothesis is that Tris-CAR-T cells can safely
and effectively be administered through the Ommaya reservoir to allow the CAR-T cells to
directly interact with the tumor cells for each patient enrolled in the study. The
primary aim of the study will be to evaluate the safety of Tris-CAR-T administration.
Secondary aims of the study will include evaluating CAR-T cell distribution within
cerebrospinal fluid and peripheral blood, tumor progress post-CAR-T cell infusion, and,
if tissue samples from multiple time points are available, also evaluate the degree of
target expression, biological characteristics of samples at diagnosis versus at
recurrence or progression.
Detailed description:
The autologous Tris-CAR-T cell, targeting both CD44 and CD133, the two inverse correlated
targets, introduced truncated IL7Ra to the intracellular domain of the CAR molecule, and
has shown ideal survival and tumor suppression in our previous studies. The cells will be
tested for safety and kinetics in this clinical trial.
All patients are required to have an Ommaya reservoir in the tumor resection cavity
before CAR-T cell infusion. Ommaya reservoir placement is done by surgery.
Autologous Tris-CAR-T cells will be manufactured via CliniMACS Instrument (Miltenyi
Biotec). Cells will be thawed and sterily filled to infuse the patients. Each infusion
will take between 5 and 10 minutes. We will then monitor the patient in the hospital for
at least 3 days after the first dose of infusion. If the first infusion is tolerated well
and the patient is assigned for multidose treatment, a second infusion may be given 28
days after the initial infusion for the first 4 patients (adverse effect assessment), and
7 days for the last 6 patients. Patients will be monitored in the hospital for no longer
than 1 day. And the subsequent infusion will be done in the same manner. The treatment
will be proceeded in the Department of Neurosurgery, Beijing Tiantan Hospital. Patients
who receive multidose treatment will need to stay in Beijing for up to 8 weeks from the
first infusion so we can monitor for side effects and will be readmitted to the hospital
if patient develops a fever. If patient develops severe fevers after discharge from the
hospital, the patient will be readmitted to the hospital for close monitoring for at
least one night for safety observation and adverse effects management.
The first 4 patients will have follow-up visits at weeks 2, 3, and 4, then at months 3,
6, and 9 post-infusion. Patients of the consecutive multidose group will have follow-up
visits at week 2, then at months 1 and 3 post-infusion. All patients receive long-term
twice a year for a total of 15 years.
Medical tests before treatment--
Before being treated, the patient will receive a series of standard medical tests:
- Physical exam
- Blood routine, serum biochemical test, kidney and liver function
- Measurements of the tumor by routine MRI
Medical tests during and after treatment--
The patient will receive standard medical tests when they are getting the infusions and
afterward:
- Physical exams
- Blood routine, serum biochemical test, kidney and liver function, serum and (or)
cerebrospinal fluid analysis
- Measurements of the tumor by MRI. Cerebrospinal fluid may be drawn from the
patient's existing Ommaya reservoir preferentially, or via lumbar puncture before
each infusion and at each time of follow-up. This procedure can be done at the
bedside under local anesthesia and about 1ml of cerebrospinal fluid will be removed.
Additional cerebrospinal fluid may be removed when intracranial hypertension occurs
or other clinical needs.
To learn more about the pharmacokinetics of autologous Tris-CAR-T cells, peripheral blood
will be obtained simultaneously with the cerebrospinal fluid collection. The amount of
blood taken will be based on clinical need, for approximately 5 mL each time.
If the tumor samples of the patients are obtained, we will request a sample to be used
for research purposes.
The patient will receive supportive care for any acute or chronic cytotoxicity, including
blood components, cytokine antagonists, glucocorticoids, antibiotics, and other
interventions as appropriate.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
1. Age: 18 years to 70 years (including cut-off values).
2. Patients with history of glioblastoma are diagnosed with recurrent glioblastoma and
residual tumor after intracranial tumor resection/biopsy performed in Beijing
Tiantan Hospital.
3. Patients who finished radiotherapy or temozolomide/bevacizumab or other drugs for at
least 4 weeks. All toxicities of prior treatment should be defined as less than or
equal to grade 1 (except for toxicities such as hair loss or leukoplakia) according
to the Common Terminology Standard for Adverse Events (CTCAE 5.0).
4. Patients who is suitable for craniotocerebrospinal fluid shunt and attachment
(Ommaya device) implantation confirmed by a competent physician.
5. Patients and/or legal representative is able to sign written informed consent.
6. Kanovsky Performance Status (KPS) ≥ 70.
7. According to the researchers' judgment, the life expectancy ≥ 8 weeks.
8. White blood cells (WBC) > 3.50×10^9/L (performed within 14 days prior to PBMC
collection unless otherwise noted).
9. Platelet ≥ 200×10^9/L (performed within 14 days prior to PBMC collection unless
otherwise noted).
10. Hemoglobin ≥ 120 g/L (performed within 14 days prior to PBMC collection unless
otherwise noted).
11. Total bilirubin ≤ 20 μmol/L (performed within 14 days prior to PBMC collection
unless otherwise noted).
12. Aspartic acid aminotransferase (AST) ≤ 2.5×42 U/L (performed within 14 days prior to
PBMC collection unless otherwise noted).
13. Alanine aminotransferase (ALT) ≤ 2.5×41 U/L (performed within 14 days prior to PBMC
collection unless otherwise noted).
14. Serum creatinine ≤ 90 μmol/L (performed within 14 days prior to PBMC collection
unless otherwise noted).
15. Blood oxygen saturation ≥ 95% (performed within 14 days prior to PBMC collection
unless otherwise noted).
16. Seronegative of the combination of human immunodeficiency virus (HIV) antibody (Ab)
(performed within 14 days prior to PBMC collection unless otherwise noted).
17. Fertile women: a negative serum pregnancy test (performed within 14 days prior to
PBMC collection unless otherwise noted).
18. The patient agrees that contraception should be used in patients of childbearing age
for at least 3 months from screening to the last infusion of Tris-CAR-T cells. The
period of childbearing age is defined as unsurgically neutered (men and women) or
without menopause for more than 1 year (women only).
Exclusion Criteria:
1. Kanovsky Performance Status (KPS) ≤ 70.
2. Highly allergic constitution or severe allergies history.
3. Those who have psychiatric or psychological diseases and cannot cooperate with
treatment and efficacy assessment.
4. Receive other drug trials within 60 days before enrollment, or receive other routine
treatment in non-experimental designs for glioblastoma, such as stereotactic
radiation therapy or placement of carmustine wafers.
5. Combined with infection, active infection, fever of unknown cause.
6. Combined with serious or unstable heart, lung, liver, kidney and hematopoietic
system diseases, including active hepatitis.
7. Combined with inflammation and immune system diseases (such as rheumatoid
arthritis), or known immunosuppressive diseases.
8. Combined with neurological diseases, such as diffuse leptomeningeal disease, or
neurodegenerative diseases.
9. Known allergies to immunotherapy and related cellular products.
10. Patients who have received any gene therapy before.
11. Long-term use of immunosuppressants is required for any reason.
12. Patients with a history of organ transplantation or who are waiting for organ
transplantation.
13. Special cases: pregnancy or lactation.
14. Other circumstances in which the investigators believe the patient is unsuitable for
this trial.
Gender:
All
Minimum age:
18 Years
Maximum age:
70 Years
Healthy volunteers:
No
Locations:
Facility:
Name:
Beijing Tiantan Hospital
Address:
City:
Beijing
Zip:
100070
Country:
China
Status:
Recruiting
Contact:
Last name:
Wei Zhang, Prof.
Phone:
+8618010212661
Email:
zhangwei02@bjtth.org
Investigator:
Last name:
You Zhai, Dr.
Email:
Sub-Investigator
Investigator:
Last name:
Guanzhang Li, Dr.
Email:
Sub-Investigator
Start date:
September 30, 2023
Completion date:
November 1, 2032
Lead sponsor:
Agency:
Beijing Tiantan Hospital
Agency class:
Other
Collaborator:
Agency:
Beijing Neurosurgical Institute
Agency class:
Other
Collaborator:
Agency:
Tasly Pharmaceutical Group Co., Ltd
Agency class:
Industry
Source:
Beijing Tiantan Hospital
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05577091
